Hormones in Hypogonadotropic Hypogonadism

Launched by MEDICAL UNIVERSITY OF VIENNA · Jun 12, 2021

Keywords

ClinConnect Summary

This clinical trial, titled "Hormones in Hypogonadotropic Hypogonadism," is looking to understand the hormonal profiles of women who have a condition called hypogonadotropic hypogonadism (HH), which is when the body does not produce certain hormones that are necessary for menstruation. The study will specifically measure hormones like anti-Müllerian hormone (AMH) and the number of small follicles in the ovaries before and after two months of treatment. The goal is to see how these hormones change with individual treatment, helping to improve our understanding of this condition.

To be eligible for this study, women aged between 18 and 35 who have not had their period for at least six months might qualify, as long as they have not been on thyroid medication and can provide consent to participate. Participants can expect to receive personalized treatment and will be monitored closely over the study period. This research aims to provide valuable insights into how hormone levels can be managed in women with this specific type of hypogonadism, potentially leading to better future treatments.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patient with HH and secondary amenorrhea. HH is defined as absence of spontaneous menstruation for ≥6 months, no abrupt menstrual bleeding after progesterone therapy, and normal or low serum FSH and LH levels.
• • The patient gave written informed consent to the study after receiving detailed information and education from medical contributors at the Department of Obstetrics and Gynecology, Medical University of Vienna.
• • Age between \>18 and \<35 years.
• Exclusion Criteria:
• • Latent or manifest hypothyroidism (TSH \>4 micromole/milliliter) or current thyroid hormone replacement therapy.
• • No existing informed consent